You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Compact Laser Drivers for Photoconductive Semicond
SBC: SCIENTIFIC APPLICATIONS & RESEARCH ASSOCIATES, INC. Topic: DTRA16A004For effective protection against radiated threats, it is important to understand not only the physics of the threats, but also to quantify the effects they have on mission-critical electrical systems. Radiated vulnerability and susceptibility testing requires delivery of high peak power and peak electric fields to distant targets. The most practical solution to simulate such environments on large ...
STTR Phase II 2018 Department of DefenseDefense Threat Reduction Agency -
Infectious Disease Diagnostics and Differentiation of Viral vs. Bacterial Infections for Point ofCare Applications
SBC: GENECAPTURE, INC. Topic: CBD15C001GeneCapture, Inc. is proposing to develop a rapid in vitro diagnostic prototype using our patented molecular-based CAPTURE (ConfirmActive Pathogens Through Unamplified RNA Expression) assay. Based on the results and experience gained in our Phase I STTR contractHDTRA1-16C-0061: Infectious Disease Diagnostics and Differentiation of Viral vs. Bacterial Infections for Point of Care Applications, we p ...
STTR Phase II 2018 Department of DefenseOffice for Chemical and Biological Defense -
Novel Circulating RNA-based Markers as Diagnostic Biomarkers of Infectious Diseases
SBC: CFD RESEARCH CORPORATION Topic: CBD18A001In resource limited settings, rapid and accurate diagnosis of infections is critical for managing potential exposures to highly virulent pathogens,whether occurring from an act of bioterrorism or a natural event. This is especially important for hard to detect intracellular bacterial andalphavirus infections, that overlap symptomatically and often treated empirically due to a lack of reliable and ...
STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense -
Marburg Virus Prophylactic Medical Countermeasure
SBC: MAPP BIOPHARMACEUTICAL, INC. Topic: CBD18A002There are currently no vaccines or therapeutics available for Marburg Virus Disease (MVD). Given the specter of weaponization and the terriblemorbidity and high mortality rate of MVD, this represents a critical threat to the operational readiness of the Warfighter. While traditionalvaccines have proven to be a huge contribution to public health, they do have some limitations especially in the cont ...
STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense -
Host-Targeted Antiviral Drugs Providing Rapid, Scalable, Stable, Broad-Spectrum MedicalCountermeasure Against Marburg Virus
SBC: EVRYS BIO LLC Topic: CBD18A002In a pandemic or exposure to weaponized Marburg virus the morbidity, mortality and social unrest that will ensue before vaccines orMilitary operating on foreign soil as well as to the population of the US Homeland. Practically all threat agents of biological origin (except forcertain non-proteinaceous toxins, typically produced by marine organisms and fungi) have their structure and vital function ...
STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense -
Marburg Virus Prophylactic Medical Countermeasure
SBC: Flow Pharma, Inc. Topic: CBD18A002Flow Pharma, Inc. is a biotechnology company in the San Francisco Bay Area developing fully synthetic cytotoxic T lymphocyte (CTL)stimulating peptide vaccines for Marburg virus. The FlowVax vaccine platform allows us to create dry powder formulations of biodegradablemicrospheres and TLR adjuvants incorporating class I and class II T cell epitopes. FlowVax vaccines can be designed for delivery by i ...
STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense